Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

计划入组 30 人 · 首次发布于 2012 年 12 月 10 日

Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy

计划入组 25 人 · 首次发布于 2017 年 7 月 26 日

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

计划入组 15 人 · 首次发布于 2012 年 7 月 26 日

Agalsidase alfa(Replagal)

Rx

Agalsidase Beta Biosidus

Agalsidase Beta Biosimilar (Generium)

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

Protalix Biotherapeutics

Israel

Chiesi's ELFABRIO Shows Promise in Phase 3 Trial for Fabry Disease with Twice-Dose Regimen

Elfabrio Shows Promise in Phase 3 BRIGHT Study for Fabry Disease

EMA Validates Less Frequent Dosing Regimen for Elfabrio in Fabry Disease